-
Purdue Pharma L.P. et al v. Teva Pharmaceuticals USA , Inc. DC CAFC
- 1:12-cv-05083
- S.D.N.Y.
- Judge: Sidney H. Stein
- Filed: 06/28/2012
- Closed: 01/14/2014
- Latest Docket Entry: 05/11/2016
- PACER
2
Plaintiffs
1
Defendant
1
Accused
Product
1
Patent-in-Suit
566
Days in
Litigation
-
Purdue Pharma L.P. et al v. Teva Pharmaceuticals USA , Inc. DC CAFC
- 1:12-cv-05083
- S.D.N.Y.
- Judge: Sidney H. Stein
- Filed: 06/28/2012
- Closed: 01/14/2014
- Latest Docket Entry: 05/11/2016
- PACER
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A thermoformed dosage form comprising: i) one or more active ingredients with abuse potential (A) selected from the group consisting of opiates and opioids, ii) optionally physiologically acceptable auxiliary substances (B), iii) at least 30% by
view more
|
Invalid
Entry 150 |
2 |
The dosage form according to claim 1, which is in the form of a tablet.
|
Invalid
Entry 150 |
5 |
A process for the production of a dosage form according to claim 1, said process comprising mixing components (A), the optionally present component (B), component (C) and the optionally present component (D) to form a mixture and, optionally after
view more
|
Invalid
Entry 150 |
7 |
A dosage form obtained by the process of claim 5.
|
Invalid
Entry 150 |
8 |
The dosage form according to claim 1, wherein the active ingredient with abuse potential (A) is oxycodone or a physiologically acceptable salt thereof.
|
Invalid
Entry 150 |